Cutting Attrition Rates in Your CNS Clinical Trials
Add bookmark
Cutting Attrition Rates in Your CNS Clinical Trials
Add bookmark
Dr. Wolfgang Eglmeier, Head of Clinical Operations Germany, Grünenthal GmbH, joins Helen Winsor from Pharma IQ, to discuss optimising clinical development in CNS. He outlines the main challenges when recruiting for CNS trials and some strategies that can be employed to aid registration here. Wolfgang also offers some insight into how attrition is tackled at Grünenthal GmbH, and the most effective ways to monitor suicidality in CNS trials. [inlinead]
Tags:
Wolfgang Eglmeier
Grünenthal
CNS
CNS clinical development
clinical operations
CNS trials
suicidality CNS trials
CNS trial process
attrition
attrition rates
